ACHIEVE-3: the first head-to-head oral GLP-1 trial —…

ACHIEVE-3 was a 52-week Phase 3 randomized controlled trial comparing orforglipron (now Foundayo) and oral semaglutide in adults with type 2 diabetes that was inadequately controlled on existing therapy.

The trial compared two dose pairs: orforglipron 12 mg versus oral semaglutide 7 mg, and orforglipron 36 mg versus oral semaglutide 14 mg. These are the maximum approved doses for each drug in the T2D setting. The primary endpoint was non-inferiority of orforglipron to oral semaglutide — the trial was designed first to ask whether orforglipron was at least as good. Superiority was tested only after non-inferiority was established.

Participants were adults with type 2 diabetes, inadequately controlled on existing therapy. This is an important framing point: the trial population had T2D. People without diabetes who take GLP-1s for weight management are a different population.

On the primary endpoint, orforglipron not only met non-inferiority but demonstrated statistical superiority at both dose comparisons.

Mean A1C reductions:

• Orforglipron 12 mg: –1.9% versus oral semaglutide 7 mg: –1.2%
• Orforglipron 36 mg: –2.2% versus oral semaglutide 14 mg: –1.4%

Weight loss followed a similar pattern. In the higher-dose comparison, Foundayo achieved a mean weight reduction of approximately 19.7 lbs versus approximately 11.0 lbs for oral semaglutide at 52 weeks.

Lilly's press release reported 57.1% greater relative A1C reduction and 73.6% greater relative weight loss at the highest dose comparison. The relative numbers are mathematically correct but reflect the starting denominators; the absolute differences (1.4 percentage points in A1C; approximately 8.7 lbs in weight) are the clinically meaningful figures.

A clinical trial that meets a superiority endpoint has shown a statistically significant difference in the pre-specified outcome between the two treatments. This does not mean the superior drug is "better" for every patient, or that the differences are clinically meaningful for every individual.

In ACHIEVE-3, the A1C differences between the two oral GLP-1s are meaningful on a population level — but individual response varies. Tolerability, dosing schedule, cost, and coverage matter alongside efficacy averages.

Dosing restrictions: Oral semaglutide requires specific dosing conditions — the tablet must be taken on an empty stomach with up to 4 oz of plain water, and you must wait at least 30 minutes before eating, drinking anything else, or taking other medications. This restriction exists because oral semaglutide's absorption depends on specific gastric conditions.

Foundayo has no food or water restrictions. It can be taken with or without food and at any time of day. This difference may affect adherence and tolerability in practice.

Approval status and indication: Foundayo was approved by the FDA in April 2026 for type 2 diabetes and cardiovascular risk reduction. The Wegovy tablet was approved for weight management in people with obesity or overweight with comorbidities. These are different FDA-approved indications. ACHIEVE-3 was conducted in a T2D population and evaluated the T2D indication.

• How these two drugs compare in people without type 2 diabetes taking a GLP-1 for weight management — that population was not studied.
• Long-term outcomes beyond 52 weeks, including cardiovascular outcomes.
• How these drugs compare on tolerability over time at real-world doses.
• How cost and insurance coverage affect real-world access and outcomes.

Foundayo's obesity/weight management indication was pending as of the time of this writing (July 2026). If and when that indication is approved, comparative efficacy for weight loss in people without T2D will be more directly relevant.

• Which oral GLP-1 does my insurance cover under my specific indication (T2D or obesity)?
• Does the dosing restriction for oral semaglutide fit my daily routine — or would a no-restriction option like Foundayo work better for me?
• Does the ACHIEVE-3 data change your recommendation for my situation?
• What does the out-of-pocket cost difference look like between these drugs under my plan?

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• PubMed — ACHIEVE-3 primary trial paper (Rosenstock et al., PMID 41765029): pubmed.ncbi.nlm.nih.gov
• Eli Lilly investor press release — ACHIEVE-3 results: investor.lilly.com
• PR Newswire — Foundayo ACHIEVE-3 detailed results, May 2026: prnewswire.com